AAM presentation delivered at the Federal Trade Commission Workshop, November 8, 2017.
The future of a sustainable competitive supply of life-saving affordable generic medicines is under threat – the result of a combination of anticompetitive behavior, market consolidation, and policy missteps. We encourage the agencies, Congress, and the public to be vigilant in assessing the potential for anticompetitive effects that may result from the market consolidation of generic purchasing between wholesalers and pharmacies.
